RxDoctor Payments Data

Olivia Chang, PA

Physician Assistant · Orange, CANPI 1649844085

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 139 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$831
  • Novartis$468
  • Atricure, Inc.$413
  • Amgen$301
  • Boehringer Ingelheim$258
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$246
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$2256%
  • Food & beverage$3,60394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$37,006
Medicare patients
220
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$310,983
EntrestoSacubitril/Valsartan110$143,404
XareltoRivaroxaban81$101,284
Praluent PenAlirocumab36$33,175
Repatha SureclickEvolocumab27$28,525
BrilintaTicagrelor20$22,862
MultaqDronedarone Hcl12$18,910
Potassium Chloride48$3,014
Atorvastatin Calcium155$2,195
Metoprolol Succinate147$1,855
Valsartan76$1,533
Ranolazine ErRanolazine15$1,100
Losartan Potassium121$1,014
Rosuvastatin Calcium41$958
ClopidogrelClopidogrel Bisulfate100$924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$310,983243 claims
NovartisEntresto$468$143,404110 claims
Johnson & JohnsonXarelto$16$101,28481 claims
AstraZenecaBrilinta$90$22,86220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →